Discover investment opportunities in Top 3 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 3 Stocks Under $2 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 3 Stocks Under $2 using our Smart AI Filter.
6 stocks found for "Top 3 Stocks Under $2"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.70 | ±100.0% | 11.6 | 0.00% | |||
0.86 | ±55.0% | 41.8 | 0.00% | |||
0.71 | ±56.0% | -26.5 | 0.00% | |||
2.07 | ±100.0% | -4.2 | 0.00% | |||
1.56 | ±82.7% | -121.0 | 0.00% | |||
0.54 | ±100.0% | -0.1 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe heavy selling pressure might have exhausted for Citius Pharmaceuticals, Inc. (CTXR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Read moreOragenics Inc (NYSE: OGEN) has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) to enable Oragenics to pursue an intranasal vaccine designed against omicron variant. The NRC cell expression technologies provide Oragenics with a platform to generate cell lines for high-yield production of spike protein antigens for existing and emerging variants of concern.
Read moreQ: Why might investors consider SNDL as a potential investment?
A: SNDL operates in the cannabis sector, which has growth potential due to increasing legalization efforts. However, profitability is often a challenge in this industry, and market competition is intense. The stock's price under $2 suggests potential volatility, appealing to risk-tolerant investors.
Q: What should investors know about the volatility of IDEX?
A: IDEX, involved in electric vehicles and fintech, operates in rapidly changing sectors. The stock price under $2 may reflect high volatility. Investors should monitor industry trends and financial health, as emerging tech markets can present both opportunities and risks.
Q: How does KNDI's market presence influence its stock appeal?
A: KNDI is a player in the electric vehicle sector, focusing on affordable EV solutions in China. This gives it an advantage in a massive market, but it faces competition from local and international brands. Its stock price and market strategy may appeal to value-oriented investors seeking exposure to EVs.
Q: Is OGEN a viable option for growth-focused investors?
A: OGEN is a biopharmaceutical company focusing on developing treatments for infections. Its stock price under $2 suggests early-stage positioning, with high potential returns if clinical trials succeed. However, investors should consider trial success rates and regulatory hurdles.
Q: Can CTXR offer stability in a volatile market?
A: CTXR, in drug development, often experiences stock price fluctuations typical of biotech companies. While it may not offer substantial market stability, some investors consider its developmental pipeline promising, but it's crucial to weigh the speculative nature of biotech investments.
Q: What are the income prospects from SENS investments?
A: SENS, focusing on glucose monitoring technology, does not currently offer dividends, reflecting its reinvestment in technology advancement. Investors interested in income should consider the company's potential capital gains over direct yield, acknowledging tech sector dynamics.